JNJ241220P157500
- 11.00
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab
Dow's 111-Point Drop Led By Losses For UnitedHealth, Verizon Shares
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | J&J: Submits Application Seeking U.S. FDA Approval of Simponi® (Golimumab) for Treatment of Pediatric Ulcerative Colitis
Johnson & Johnson is suing a division of Cigna, accusing it of misappropriating a financial aid fund.
On December 16, Gleno Exchange reported that Johnson & Johnson has filed a lawsuit against a division of Cigna, accusing the medical insurance company of collaborating with pharmaceutical benefit managers to steal Johnson & Johnson's financial assistance funds, which are specifically designated for patients using some of Johnson & Johnson's high stock price drugs.
Insider Trades: Kroger, Johnson & Johnson Among Notable Names This Week
Express News | Johnson & Johnson Shares up 0.4%
Express News | Cigna Shares Pare Gains, Last up 0.2%; Wall Street Journal Reports Johnson & Johnson Has Sued Divisions of Cigna
"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical Company Claims Cigna Units Worked With SaveOn and Caused It to Pay More Than $100 Million in Copay Assistance Than It Would Have Otherwise" - WSJ
Johnson & Johnson Options Trading: A Deep Dive Into Market Sentiment
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ACTION Centers Collaborate With Johnson & Johnson MedTech to Secure FDA Labeling for Impella Support System in Pediatric Patients
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients
Today's Analyst Rating | Citi Cuts Its Price Target Cut on Johnson & Johnson to $175, Deutsche Bank Upgrades Coca-Cola to Buy
Dec 12, Wall Street analysts have updated their stock ratings today including $Johnson & Johnson(JNJ.US)$ and $Coca-Cola(KO.US)$.